Drugs that tap into macrophages' natural appetites, find ways to reduce their immunosuppressive effects or reduce their presence in the tumour milieu could complement existing immuno-oncology strategies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R
Communications Chemistry Open Access 03 January 2024
-
Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma
BMC Cancer Open Access 21 October 2020
-
Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models
Journal of Experimental & Clinical Cancer Research Open Access 22 August 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Morrison, C. Immuno-oncologists eye up macrophage targets. Nat Rev Drug Discov 15, 373–374 (2016). https://doi.org/10.1038/nrd.2016.111
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.111
This article is cited by
-
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R
Communications Chemistry (2024)
-
Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment
Cellular Oncology (2023)
-
Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy
Gastric Cancer (2021)
-
Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma
BMC Cancer (2020)
-
Human chimeric antigen receptor macrophages for cancer immunotherapy
Nature Biotechnology (2020)